Fifth data and safety monitoring board meeting of the EffiKIR trial recommends continuation without modification

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the Data and Safety Monitoring Board (“DSMB”) completed its fifth assessment of the EffiKIR study and recommended continuation of the trial without modification.

Enrolment in the EffiKIR study was completed in July 2014 and data on the primary endpoint, Leukemia-Free Survival, are expected in the second quarter of 2016.

As specified in the study protocol, the DSMB meets every six months to examine the safety data accumulated during progress of the trial. A DSMB is a committee of independent clinical research experts who review data in ongoing clinical trials with particular attention to safety. DSMBs are customarily established for large randomized multisite studies.